Multiple Myeloma News
Best Treatment for Newly Diagnosed Multiple Myeloma
A recent article published in JAMA Oncology1 questions whether VRd should remain as the standard of care (SOC) in newly diagnosed multiple myeloma. Careful analysis of the ENDURANCE (E1A11) phase III trial2 raises the question whether VRd continues to be the SOC for...
FDA approves isatuximab in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior...
FDA Approves First CAR-T Cell Therapy ide-cel for R/R Myeloma
The U.S. Food and Drug Administration Approved Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel) (ide-cel), On Friday March 26th. Ide-cel is the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. The treatment was...
Top Headlines and Journal Articles for the Week of March 22, 2021
Here is a roundup of articles and news stories the MYELOMA360 team found interesting this week. Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions Researchers at Sylvester Comprehensive Cancer Center at the...
Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma,...
COVID-19 in a Multiple Myeloma Patient
Multiple myeloma patients are often treated with immunomodulatory drugs, proteasome inhibitors or monoclonal antibodies until disease progression. Chronic therapy in combination with the underlying disease frequently results in severe humoral and cellular...
New Target for Multiple Myeloma
A lot of progress has been made in myeloma, but there remains unmet need of patients who’ve exhausted many treatment options. In a new prospective, prospective, multicenter, single-arm clinical trial study published in Nature Medicine, the researchers used...
Optimizing the Use of MRD Testing in Multiple Myeloma
Achieving minimal residual disease (MRD) negativity is an independent prognostic factor for survival in multiple myeloma (MM); however there remain questions about the optimal use of MRD. In a review published in Pathology, the journal of the Royal College of...
Switching Select Older Patients to Low Dose of Lenalidomide and Discontinuing Dex is Safe and Effective
A new study published in Blood found that switching select older patients to a lower dose of lenalidomide and discontinuing dexamethasone after nine months was not only safe, but it also yielded similar outcomes as compared with patients who received continuous Rd....
Daratumumab Monotherapy Demonstrates Efficacy in R/R Myeloma
A recent article published Feb. 2, 2021 in the Annals of Hematology demonstrated efficacy and safety of daratumumab (DARA) monotherapy in real-world patients. The GIMEMA Lazio group reported experience in 62 patients with relapsed/ refractory myeloma who had...
Other Oncology News
Additional Myeloma News
Powered by:
- EC Approves New Sarclisa Indication
- Four Drugs Upfront Yield ‘Unprecedented’ Response in Myeloma
- European Commission Approves Second Indication Of Sarclisa® (Isatuximab) For Relapsed Multiple Myeloma
- Studies Suggest People with Blood Cancers May Not Be Optimally Protected after COVID-19 Vaccination
- Personalized Cancer Vaccine Given After Adjuvant Therapy Safe, Shows Early Efficacy in Multiple Tumor Types
- Molecular Templates to Prioritize Next-Generation ETB Candidates
- SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
- FDA Approves Isatuximab-Irfc For Multiple Myeloma
- FDA Approves Sarclisa® (Isatuximab) in Combination With Carfilzomib And Dexamethasone For Patients With Relapsed or Refractory Multiple Myeloma
- International Myeloma Foundation Says FDA Approval of Bristol Myers Squibb’s and bluebird bio’s CAR T-Cell Immunotherapy Treatment for Multiple Myeloma Is Welcome News for Patients
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.